Human FCGR3A Stable Cell Line - A375

The FCGR3A gene plays a pivotal and foundational role within the human immune system, serving as an indispensable bridge between innate and adaptive immunity. This gene encodes a transmembrane receptor protein capable of binding to the Fc fragment of Immunoglobulin G (IgG) antibodies with low-to-intermediate affinity. In the human body, FCGR3A receptors are predominantly expressed on the surfaces of Natural Killer (NK) cells, monocytes, and macrophages. When antibodies bind to specific target cells—such as virus-infected cells or malignant tumor cells—the FCGR3A receptors on the surface of immune effector cells recognize and bind to the exposed Fc regions of these antibodies. This binding event triggers a cascade of potent intracellular signaling events, a process typically mediated by "Immunoreceptor Tyrosine-based Activation Motifs" (ITAMs) located on associated adaptor proteins. The ultimate outcome of this signaling pathway is the induction of "Antibody-Dependent Cell-Mediated Cytotoxicity" (ADCC)—a critical immune defense mechanism wherein effector cells release cytotoxic granules containing perforin and granzymes, thereby actively inducing apoptosis in the target cells.

The "Human FCGR3A Stable Cell Line—A375" has been specifically designed and engineered to provide robust support for immunological research and the development of novel biotherapeutic agents. This specialized cell product was constructed by stably and permanently transfecting the human FCGR3A gene into the A375 host cell line. The A375 cell line is a well-characterized malignant melanoma cell line, renowned for its rapid growth kinetics and excellent adaptability to continuous culture. The primary application of this stable cell line lies in the high-throughput screening and functional characterization of therapeutic monoclonal antibodies, particularly in the precise assessment of their Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) potential. Drug developers rely heavily on this standardized cellular model to conduct extensive Fc-region engineering studies, thereby enabling the systematic determination of whether precise modifications to the Fc regions of candidate antibodies enhance or diminish their binding affinity for the FCGR3A receptor.